Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Vassiliadis, Efstathios ^a,b   Rasmussen, Lars M ^c   Byrjalsen, Inger ^a   Larsen, Dorthe V ^a   Chaturvedi, Rajiv ^d   Hosbond, Susanne ^c   Saabye, Lotte ^c   Diederichsen, Axel C P ^c   Genovese, Federica ^a   Duffin, Kevin L ^e   Zheng, Qinlong ^f   Chen, Xiaoliang ^f   Leeming, Diana J ^a   Christiansen, Claus ^a   Karsdal, Morten A ^a,c  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e ELI LILLY AND COMPANY   (United States)

^f Nordic Bioscience Beijing   (China)

Author keywords

Acute myocardial infarction; Biomarker; Cardiovascular; CVD; MMP 12; Neoepitope; Titin

Indexed keywords

ASPARAGINYLVALYLTHREONYLVALYLGLUTAMYLALANYLARGINYLLEUCYLISOLEUCYLLYSINE; CONNECTIN; MACROPHAGE ELASTASE; PEPTIDE FRAGMENT; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASE CONTROL STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; SEROLOGY;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MATRIX METALLOPROTEINASE 12; MIDDLE AGED; MUSCLE PROTEINS; PROTEIN KINASES; PROTEOLYSIS; ROC CURVE;

EID: 84863481028     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-140     Document Type: Article

References (61)

1. LeWinter MM, Wu Y, Labeit S, Granzier H. Cardiac titin: structure, functions and role in disease. Clin Chim Acta 2007, 375(1-2):1-9.
2. Fukuda N, Terui T, Ishiwata S, Kurihara S. Titin-based regulations of diastolic and systolic functions of mammalian cardiac muscle. J Mol Cell Cardiol 2010, 48(5):876-881. 10.1016/j.yjmcc.2009.11.013, 19962382.
3. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation 2010, 121(19):2137-2145. 10.1161/CIRCULATIONAHA.109.860171, 2905226, 20479164.
4. Wu Y, Bell SP, Trombitas K, et al. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 2002, 106(11):1384-1389. 10.1161/01.CIR.0000029804.61510.02, 12221057.
5. Sutko JL, Publicover NG, Moss RL. Titin: an elastic link between length and active force production in myocardium. Circulation 2001, 104(14):1585-1587.
6. Granzier HL, Irving TC. Passive tension in cardiac muscle: contribution of collagen, titin, microtubules, and intermediate filaments. Biophys J 1995, 68(3):1027-1044. 10.1016/S0006-3495(95)80278-X, 1281826, 7756523.
7. Jaber WA, Maniu C, Krysiak J, et al. Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insight. Circ Heart Fail 2008, 1(3):192-199. 10.1161/CIRCHEARTFAILURE.108.768465, 2779561, 19808289.
8. Hein S, Gaasch WH, Schaper J. Giant molecule titin and myocardial stiffness. Circulation 2002, 106(11):1302-1304. 10.1161/01.CIR.0000031760.65615.3B, 12221041.
9. LeWinter MM. Titin isoforms in heart failure: are there benefits to supersizing?. Circulation 2004, 110(2):109-111. 10.1161/01.CIR.0000137284.17083.93, 15249515.
10. Bang ML, Centner T, Fornoff F, et al. The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system. Circ Res 2001, 89(11):1065-1072. 10.1161/hh2301.100981, 11717165.
11. Freiburg A, Trombitas K, Hell W, et al. Series of exon-skipping events in the elastic spring region of titin as the structural basis for myofibrillar elastic diversity. Circ Res 2000, 86(11):1114-1121. 10.1161/01.RES.86.11.1114, 10850961.
12. Cazorla O, Freiburg A, Helmes M, et al. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000, 86(1):59-67. 10.1161/01.RES.86.1.59, 10625306.
13. Linke WA. Sense and stretchability: the role of titin and titin-associated proteins in myocardial stress-sensing and mechanical dysfunction. Cardiovasc Res 2008, 77(4):637-648.
14. Chaturvedi RR, Herron T, Simmons R, et al. Passive stiffness of myocardium from congenital heart disease and implications for diastole. Circulation 2010, 121(8):979-988. 10.1161/CIRCULATIONAHA.109.850677, 20159832.
15. Thijssen VL, Borgers M, Lenders MH, et al. Temporal and spatial variations in structural protein expression during the progression from stunned to hibernating myocardium. Circulation 2004, 110(21):3313-3321. 10.1161/01.CIR.0000147826.13480.99, 15545518.
16. Nagueh SF, Shah G, Wu Y, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 2004, 110(2):155-162. 10.1161/01.CIR.0000135591.37759.AF, 15238456.
17. Peng J, Raddatz K, Molkentin JD, et al. Cardiac hypertrophy and reduced contractility in hearts deficient in the titin kinase region. Circulation 2007, 115(6):743-751. 10.1161/CIRCULATIONAHA.106.645499, 17261657.
18. Linke WA. Titin stiffness in heart disease. Circulation 2003, 107(11):e73. 10.1161/01.CIR.0000060810.93701.22, 12654620.
19. Neagoe C, Kulke M, . del MF et al Titin isoform switch in ischemic human heart disease. Circulation 2002, 106(11):1333-1341. del MF et al.
20. Makarenko I, Opitz CA, Leake MC, et al. Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res 2004, 95(7):708-716. 10.1161/01.RES.0000143901.37063.2f, 15345656.
21. Van HL, Borbely A, Niessen HW, et al. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation 2006, 113(16):1966-1973. 10.1161/CIRCULATIONAHA.105.587519, 16618817.
22. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009, 14(3):181-202. 10.1080/13547500902777608, 19399662.
23. Vassiliadis E, Veidal SS, Simonsen H, et al. Immunological detection of the type V collagen propeptide fragment, PVCP-1230, in connective tissue remodeling associated with liver fibrosis. Biomarkers 2011, 5:426-433.
24. Vassiliadis E, Larsen DV, Clausen RE, et al. Measurement of CO3-610, a Potential Liver Biomarker Derived from Matrix Metalloproteinase-9 Degradation of Collagen Type III, in a Rat Model of Reversible Carbon-Tetrachloride-Induced Fibrosis. Biomark Insights 2011, 6:49-58. 3076019, 21499440.
25. Vassiliadis E, Veidal SS, Barascuk N, et al. Measurement of matrix metalloproteinase 9-mediated collagen type III degradation fragment as a marker of skin fibrosis. BMC Dermatol 2011, 11:6. 10.1186/1471-5945-11-6, 3072322, 21447148.
26. Veidal SS, Vassiliadis E, Bay-Jensen AC, Tougas G, Vainer B, Karsdal MA. Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 2010, 3(1):5. 10.1186/1755-1536-3-5, 2860343, 20359335.
27. Barascuk N, Vassiliadis E, Larsen L, et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen-A novel biomarker of atherosclerotic plaque remodeling. Clin Biochem 2011, 44(10-11):900-906.
28. Kuznetsova T, Herbots L, Lopez B, et al. Prevalence of left ventricular diastolic dysfunction in a general population. Circ Heart Fail 2009, 2(2):105-112. 10.1161/CIRCHEARTFAILURE.108.822627, 19808325.
29. de Lemos JA. Biomarkers in Heart Disease 2008, Malden, MA: Blackwell publishing and American Heart Association.
30. Jackson CE, Dalzell JR, Gardner RS. Prognostic utility of cardiac troponin in heart failure: a novel role for an established biomarker. Biomark Med 2009, 3(5):483-493. 10.2217/bmm.09.38, 20477518.
31. Park JP, Cropek DM, Banta S. High affinity peptides for the recognition of the heart disease biomarker troponin I identified using phage display. Biotechnol Bioeng 2010, 105(4):678-686.
32. Rosalki SB, Roberts R, Katus HA, Giannitsis E, Ladenson JH, Apple FS. Cardiac biomarkers for detection of myocardial infarction: perspectives from past to present. Clin Chem 2004, 50(11):2205-2213. 10.1373/clinchem.2004.041749, 15502101.
33. O'Brien PJ. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity. Toxicology 2008, 245(3):206-218. 10.1016/j.tox.2007.12.006, 18249481.
34. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122(20):2039-2047. 10.1161/CIRCULATIONAHA.109.930222, 3057897, 21041693.
35. Linke WA. Molecular giant vulnerable to oxidative damage: titin joins the club of proteins degraded by matrix metalloproteinase-2. Circulation 2010, 122(20):2002-2004. 10.1161/CIRCULATIONAHA.110.985317, 21041688.
36. Zhen EY, Brittain IJ, Laska DA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008, 58(8):2420-2431. 10.1002/art.23654, 18668564.
37. Johnson JL, George SJ, Newby AC, Jackson CL. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A 2005, 102(43):15575-15580. 10.1073/pnas.0506201102, 1266110, 16221765.
38. Combet C, Blanchet C, Geourjon C, Deleage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000, 25(3):147-150. 10.1016/S0968-0004(99)01540-6, 10694887.
39. Musco G, Tziatzos C, Schuck P, Pastore A. Dissecting titin into its structural motifs: identification of an alpha helix near the N-terminus. Biochemistry 1995, 34:553-561. 10.1021/bi00002a021, 7819249.
40. Gefter ML, Margulies DH, Scharff MD. A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells. Somatic Cell Genet 1977, 3(2):231-236. 10.1007/BF01551818, 605383.
41. Diederichsen AC, Sand NP, Norgaard B, et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. Eur J Cardiovasc Prev Rehabil 2011,
42. Lambert JM, Lopez EF, Lindsey ML. Macrophage roles following myocardial infarction. Int J Cardiol 2008, 130(2):147-158. 10.1016/j.ijcard.2008.04.059, 2857604, 18656272.
43. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003, 349(17):1587-1589. 10.1056/NEJMp038136, 14573728.
44. Stampfer MJ, Ridker PM, Dzau VJ. Risk factor criteria. Circulation 2004, 109(25 Suppl 1):IV3-IV5.
45. Orn S, Manhenke C, Squire IB, Ng L, Anand I, Dickstein K. Plasma MMP-2, MMP-9 and N-BNP in Long-Term Survivors Following Complicated Myocardial Infarction: Relation to Cardiac Magnetic Resonance Imaging Measures of Left Ventricular Structure and Function. Journal of Cardiac Failure 2007, 13(10):843-849. 10.1016/j.cardfail.2007.07.006, 18068618.
46. Riches K, Morley ME, Peers C, Porter KE. Hypoxic inhibition of MMP-2 activation and invasion in human cardiac myofibroblasts. J Mol Cell Cardiol 2008, 44(4):737-738.
47. Bellosta S, Gomaraschi M, Canavesi M, et al. Inhibition of MMP-2 activation and release as a novel mechanism for HDL-induced cardioprotection. FEBS Letters 2006, 580(25):5974-5978. 10.1016/j.febslet.2006.10.006, 17052715.
48. Turner NA, Aley PK, Hall KT, et al. Simvastatin inhibits TNF[alpha]-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 2007, 43(2):168-176. 10.1016/j.yjmcc.2007.05.006, 17560598.
49. Zhou HZ, Ma X, Gray MO, et al. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophysical Res Comm 2007, 358(1):189-195.
50. Wohlschlaeger J, Stubbe HD, Schmitz KJ, et al. Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model. Pathology Res Prac 2005, 201(12):809-817.
51. Nichol JW, Engelmayr J, Cheng M, Freed LE. Co-culture induces alignment in engineered cardiac constructs via MMP-2 expression. Biochem Biophysical Res Comm 2008, 373(3):360-365.
52. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004, 109(11):1408-1414. 10.1161/01.CIR.0000121728.14930.DE, 14993123.
53. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: [`]Embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010, 48(3):445-453. 10.1016/j.yjmcc.2009.09.013, 19799912.
54. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998, 102(11):1900-1910. 10.1172/JCI2182, 509141, 9835614.
55. Johnson JL, Devel L, Czarny B, et al. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2011, 31(3):528-535. 10.1161/ATVBAHA.110.219147, 3041652, 21212406.
56. Didangelos A, Yin X, Mandal K, et al. Extracellular matrix composition and remodeling in human abdominal aortic aneurysms: a proteomics approach. Mol Cell Proteomics 2011, 10(8):M111.
57. Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006, 113(16):1993-2001. 10.1161/CIRCULATIONAHA.105.596031, 16636188.
58. Ikonomidis JS, Jones JA, Barbour JR, et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation 2006, 114(1 Suppl):I365-I370.
59. Nar H, Werle K, Bauer MMT, Dollinger H, Jung B. Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. J Mol Biol 2001, 312(4):743-751. 10.1006/jmbi.2001.4953, 11575929.
60. Benoit M, Thuny F, Le PY, et al. The transcriptional programme of human heart valves reveals the natural history of infective endocarditis. PLoS One 2010, 5(1):e8939. 10.1371/journal.pone.0008939, 2812508, 20126625.
61. Munoz-Luque J, Ros J, Fernandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008, 324(2):475-483. 2887659, 18029545.